Jan 6 (Reuters) - Denali Therapeutics ( DNLI ) said on

Monday its experimental drug failed to meet the main goal of a

mid-to-late stage trial involving patients with amyotrophic

lateral sclerosis (ALS), a fatal neurodegenerative disease.

Shares of the drug developer were down 6.6% in extended

trade following the announcement.

The study's main goal was to demonstrate a change in disease

severity over time and increase survival, comparing DNL343 to a

placebo, as measured by a specific scale.

"We remain deeply committed to fully understanding the

effects of DNL343 in ALS and will further evaluate the data

before determining next steps", said Merit Cudkowicz, the

study's principal investigator.

A more comprehensive analysis of the study results will

become available later in 2025, according to Carole Ho, the

company's medical chief.